Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer-Reference-Cited by-同舟云学术

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

Published:2009-06-12 Issue:5933 Volume:324 Page:1457-1461
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Olive Kenneth P.¹,Jacobetz Michael A.¹,Davidson Christian J.²,Gopinathan Aarthi¹²,McIntyre Dominick¹,Honess Davina¹,Madhu Basetti¹,Goldgraben Mae A.¹,Caldwell Meredith E.¹,Allard David¹,Frese Kristopher K.¹,DeNicola Gina¹²,Feig Christine¹,Combs Chelsea²,Winter Stephen P.¹,Ireland-Zecchini Heather¹,Reichelt Stefanie¹,Howat William J.¹,Chang Alex³,Dhara Mousumi³,Wang Lifu²⁴,Rückert Felix⁵,Grützmann Robert⁵,Pilarsky Christian⁵,Izeradjene Kamel⁶,Hingorani Sunil R.⁶,Huang Pearl⁷,Davies Susan E.⁸,Plunkett William⁹,Egorin Merrill¹⁰,Hruban Ralph H.³,Whitebread Nigel¹¹,McGovern Karen¹¹,Adams Julian¹¹,Iacobuzio-Donahue Christine³,Griffiths John¹,Tuveson David A.¹

Affiliation:

1. Cancer Research UK, Cambridge Research Institute, The Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK.

2. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.

3. Departments of Oncology and Pathology, The Sol Goldman Pancreatic Cancer Research Center, Sidney Cancer Center and Johns Hopkins University, Baltimore, MD 21287, USA.

4. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

5. Department of Surgery, University Hospital Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

6. Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center (FHCRC), and University of Washington, Seattle, WA 98109, USA.

7. Oncology Franchise, Merck and Company, North Wales, PA 19454, USA.

8. Department of Histopathology, Addenbrooke’s Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge CB2 2QQ, UK.

9. M. D. Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.

10. Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.

11. Infinity Pharmaceuticals, Cambridge, MA 01239, USA.

Abstract

It's All in the Delivery Pancreatic cancer is almost universally associated with a poor prognosis, in part because the tumors are resistant to chemotherapeutic drugs. Working with a mouse tumor model that displays many features of the human disease, Olive et al. (p. 1457 , published online 21 May; see the Perspective by

Olson and Hanahan

) found that the tumors were poorly vascularized, a factor likely to impede drug delivery. Treatment of the mice with the chemotherapeutic drug gemcitabine in combination with a drug that depletes tumor-associated stromal tissue led to an increase in tumor vasculature, enhanced delivery of gemcitabine, and a delay in disease progression. Thus, drugs targeting the tumor stroma may merit investigation as a way to enhance the efficacy of conventional chemotherapy for pancreatic cancer.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference27 articles.

1. Pancreatic cancer

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

4. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

5. Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma

Cited by 2613 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of AMPK activation by extracellular matrix stiffness in pancreatic cancer;Genes & Diseases;2024-05

2. Novel treatment system using endoscopic ultrasound-guided high-intensity focused ultrasound: A proof-of-concept study;Pancreatology;2024-02

3. Modulating pancreatic cancer microenvironment: The efficacy of Huachansu in mouse models via TGF-β/Smad pathway;Journal of Ethnopharmacology;2024-02

4. Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1;Cell Death Discovery;2024-01-29

5. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy;Nature Cancer;2024-01-24